Available Technology

The Use of GNRH and Analogs Thereof for the Prevention and Treatment of Pet Ferret Adrenocortical Hyperplasia

Adrenocortical disease (ACD) in ferrets develops as a result of increased concentration of Lutenizing Hormone (LH) on adrenal LH receptors.  This increase in LH often results from neutering of male or female ferrets. Neutered ferrets have no negative feedback of the ovarian or testicular hormone and as a result LH is elevated 3 to 10 times normal.  Elevates LH may be prevented and/or treated by injection of GnRH vaccine.  Administration of GnRH produces antibodies to endogenous GnRH. The GnRH-anti-GnRH immune-complex is ineffective in stimulating the release of LH and Follicle Stimulating Hormone (FSH) in the anterior pituitary resulting drop in concentration of LH in the systemic circulation.  This reduction in LH significantly reduces the occurrence or clinical symptoms of ACD.

Applications

  • ACD is the leading cause of death among European ferrets
  • Treatment of ferrets with the GnRH provides long term relief from ACD for a period of a year or more.
  • European ferrets are the third most common pet in the United States, numbering more than 300,000.
Patent Number: 
8,927,495
Patent Issue Date: 
January 6, 2015
Lab Representatives
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin